Hexarelin (GHRP-6 Analogue) Research Overview

Simplified Summary

Hexarelin (His-D-2MeTrp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide designed to potently stimulate growth hormone secretion through activation of the ghrelin receptor (GHSR-1a) in the pituitary gland and hypothalamus. Preclinical research has characterised its pharmacological profile across both pituitary GH-releasing activity and cardiovascular tissue effects mediated through CD36 receptor engagement.

A distinctive feature of hexarelin's preclinical research profile is its ability to engage CD36, a multifunctional scavenger receptor expressed in cardiac tissue, independent of its ghrelin receptor activity. Preclinical cardiovascular studies have used hexarelin as a pharmacological tool to study CD36 biology in cardiac cells and animal models of cardiac function.

Key Findings Reported in Preclinical Models

• Potent growth hormone release stimulation in preclinical animal models, with hexarelin characterised as one of the most potent synthetic GHRPs in standardised GH secretagogue assays.
• Ghrelin receptor (GHSR-1a) binding and downstream signalling characterisation in cell-based systems.
• Cardioprotective effects in preclinical cardiac ischaemia models, with hexarelin-treated animal cohorts showing improved cardiac function measures following experimentally induced injury.
• CD36 receptor engagement in cardiac tissue characterised in preclinical binding studies.
• GH-independent cardiovascular effects characterised in preclinical studies using GH-deficient animal models to dissect GH-mediated from direct cardiac effects.

Introduction

Hexarelin belongs to the growth hormone-releasing peptide family, synthetic compounds developed to mimic aspects of ghrelin's GH-stimulatory activity. It is structurally related to GHRP-6 with modifications that increase its potency at GHSR-1a. Its preclinical cardiovascular research profile — distinct from other GHRPs due to CD36 engagement — has made it a compound of interest in cardiac biology research beyond its GH secretagogue properties.

Research Applications

• Ghrelin receptor pharmacology research using hexarelin to characterise GHSR-1a signalling and GH secretagogue mechanisms in pituitary cell systems.
• Cardiac biology research examining CD36-mediated and GH-mediated cardiovascular effects in relevant preclinical animal models.
• GH axis biology studies comparing hexarelin's GH-stimulatory profile with other GHRPs and GHRH analogues.
• Cardioprotection research in preclinical ischaemia-reperfusion models examining the mechanisms underlying hexarelin's cardiac tissue effects.